208 related articles for article (PubMed ID: 29770901)
1. Factors impacting unbound vancomycin concentrations in neonates and young infants.
Smits A; Pauwels S; Oyaert M; Peersman N; Spriet I; Saegeman V; Allegaert K
Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1503-1510. PubMed ID: 29770901
[TBL] [Abstract][Full Text] [Related]
2. Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board?
De Cock PA; Desmet S; De Jaeger A; Biarent D; Dhont E; Herck I; Vens D; Colman S; Stove V; Commeyne S; Vande Walle J; De Paepe P
J Antimicrob Chemother; 2017 Mar; 72(3):801-804. PubMed ID: 27999035
[TBL] [Abstract][Full Text] [Related]
3. Factors impacting unbound vancomycin concentrations in different patient populations.
Oyaert M; Spriet I; Allegaert K; Smits A; Vanstraelen K; Peersman N; Wauters J; Verhaegen J; Vermeersch P; Pauwels S
Antimicrob Agents Chemother; 2015 Nov; 59(11):7073-9. PubMed ID: 26349820
[TBL] [Abstract][Full Text] [Related]
4. Cefazolin plasma protein binding and its covariates in neonates.
Smits A; Kulo A; Verbesselt R; Naulaers G; de Hoon J; Vermeersch P; Allegaert K
Eur J Clin Microbiol Infect Dis; 2012 Dec; 31(12):3359-65. PubMed ID: 22833246
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates.
De Cock RF; Smits A; Allegaert K; de Hoon J; Saegeman V; Danhof M; Knibbe CA
J Antimicrob Chemother; 2014 May; 69(5):1330-8. PubMed ID: 24492261
[TBL] [Abstract][Full Text] [Related]
6. Actual body weight-based vancomycin dosing in neonates.
Pokorná P; Šíma M; Černá O; Allegaert K; Tibboel D; Slanař O
J Chemother; 2019 Oct; 31(6):307-312. PubMed ID: 30983533
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle.
Allegaert K; Flint R; Smits A
Expert Opin Drug Metab Toxicol; 2019 Sep; 15(9):735-749. PubMed ID: 31402708
[No Abstract] [Full Text] [Related]
8. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.
Mehrotra N; Tang L; Phelps SJ; Meibohm B
Pharmacotherapy; 2012 May; 32(5):408-19. PubMed ID: 22488303
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and dose requirements of vancomycin in neonates.
Grimsley C; Thomson AH
Arch Dis Child Fetal Neonatal Ed; 1999 Nov; 81(3):F221-7. PubMed ID: 10525029
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin prescription in neonates and young infants: toward a simplified dosage.
Oudin C; Vialet R; Boulamery A; Martin C; Simon N
Arch Dis Child Fetal Neonatal Ed; 2011 Sep; 96(5):F365-70. PubMed ID: 21378399
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring.
Zhao W; Lopez E; Biran V; Durrmeyer X; Fakhoury M; Jacqz-Aigrain E
Arch Dis Child; 2013 Jun; 98(6):449-53. PubMed ID: 23254142
[TBL] [Abstract][Full Text] [Related]
13. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I
BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193
[TBL] [Abstract][Full Text] [Related]
14. Empirical Vancomycin Dosing in Pediatric Patients with Congenital Heart Disease and the Impact of Cardiopulmonary Bypass on Trough Concentrations.
Thomas CA; Picone A; Menon S; Willis BC
Pharmacotherapy; 2017 Nov; 37(11):1341-1346. PubMed ID: 28833385
[TBL] [Abstract][Full Text] [Related]
15. Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.
Ringenberg T; Robinson C; Meyers R; Degnan L; Shah P; Siu A; Sturgill M
Pediatr Infect Dis J; 2015 Jul; 34(7):742-7. PubMed ID: 25629890
[TBL] [Abstract][Full Text] [Related]
16. Individualized Empiric Vancomycin Dosing in Neonates Using a Model-Based Approach.
Frymoyer A; Stockmann C; Hersh AL; Goswami S; Keizer RJ
J Pediatric Infect Dis Soc; 2019 May; 8(2):97-104. PubMed ID: 29294072
[TBL] [Abstract][Full Text] [Related]
17. Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data.
Germovsek E; Osborne L; Gunaratnam F; Lounis SA; Busquets FB; Standing JF; Sinha AK
J Antimicrob Chemother; 2019 Apr; 74(4):1003-1011. PubMed ID: 30668696
[TBL] [Abstract][Full Text] [Related]
18. Measuring unbound versus total vancomycin concentrations in serum and plasma: methodological issues and relevance.
Stove V; Coene L; Carlier M; De Waele JJ; Fiers T; Verstraete AG
Ther Drug Monit; 2015 Apr; 37(2):180-7. PubMed ID: 25072945
[TBL] [Abstract][Full Text] [Related]
19. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation.
Asbury WH; Darsey EH; Rose WB; Murphy JE; Buffington DE; Capers CC
Ann Pharmacother; 1993 Apr; 27(4):490-6. PubMed ID: 8477127
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.
Jacqz-Aigrain E; Leroux S; Thomson AH; Allegaert K; Capparelli EV; Biran V; Simon N; Meibohm B; Lo YL; Marques R; Peris JE; Lutsar I; Saito J; Nakamura H; van den Anker JN; Sharland M; Zhao W
J Antimicrob Chemother; 2019 Aug; 74(8):2128-2138. PubMed ID: 31049551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
